Intromedic "Establishes US Corporation... Enters Home Care Market"

[Asia Economy Reporter Hyunseok Yoo] Intromedic announced on the 13th that it will establish a local subsidiary in the United States, IntroMedic Americo Inc. The company plans to enter the home care market with capsule endoscopes and COVID-19 (novel coronavirus infection) diagnostic kits.

The capsule endoscope allows observation of areas such as the small intestine, where conventional tube-type endoscopes have difficulty reaching. Therefore, the company explained that it is possible to diagnose unexplained abdominal pain, diarrhea, bleeding, Crohn's disease, and small intestine tumors. In March last year, the company also developed a capsule endoscope capable of effectively diagnosing the esophagus and stomach in collaboration with the Electronics and Telecommunications Research Institute (ETRI) and is currently pursuing domestic and international certifications.

The COVID-19 diagnostic kit is under a global distribution agreement with a gene analysis specialist company. This diagnostic kit is in the final stage of clinical testing and detects the genetic material of the COVID-19 virus using isothermal amplification based on real-time reverse transcription polymerase chain reaction. An Intromedic official stated, "If we cooperate with home care companies providing personal nursing services and home hospice care, we expect to quickly penetrate the market," adding, "In the United States, by 2030, the baby boomer generation will be aged 65 or older, and a large demand from retired elderly is anticipated." He continued, "Through the establishment of the local subsidiary in the United States, we will actively carry out marketing activities and strengthen services that can respond more efficiently to customer needs through direct management of the U.S. market."

This content was produced with the assistance of AI translation services.